^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunostimulant

    Related drugs:
    1d
    RZVRheum: Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases (clinicaltrials.gov)
    P4, N=2005, Active, not recruiting, University of Sao Paulo General Hospital | Trial completion date: Dec 2027 --> Jun 2032
    Trial completion date
    1d
    A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19 (clinicaltrials.gov)
    P3, N=330, Recruiting, BioNTech SE | Not yet recruiting --> Recruiting
    Enrollment open
    1d
    A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea (clinicaltrials.gov)
    P=N/A, N=3000, Recruiting, Sanofi | Trial completion date: Apr 2030 --> Sep 2029 | Trial primary completion date: Apr 2030 --> Sep 2029 | Not yet recruiting --> Recruiting
    Enrollment open • Trial completion date • Trial primary completion date
    1d
    A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer (clinicaltrials.gov)
    P1, N=56, Recruiting, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition • First-in-human
    |
    BRAF (B-raf proto-oncogene)
    |
    PD-L1 expression • BRAF mutation
    |
    Keytruda (pembrolizumab) • MQ710
    1d
    IRB00210915: Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer (clinicaltrials.gov)
    P1, N=27, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Aug 2025 --> Jun 2027 | Trial primary completion date: Aug 2025 --> Jun 2027
    Trial completion date • Trial primary completion date • Mismatch repair
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Hiltonol (poly-ICLC) • KRAS peptide vaccine
    1d
    An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) (clinicaltrials.gov)
    P2, N=267, Active, not recruiting, ModernaTX, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Sep 2029 --> Nov 2032 | Trial primary completion date: Sep 2029 --> Nov 2032
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • intismeran autogene (mRNA-4157)
    1d
    Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies (clinicaltrials.gov)
    P=N/A, N=600, Recruiting, Canadian Immunization Research Network | Not yet recruiting --> Recruiting
    Enrollment open
    1d
    A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients (clinicaltrials.gov)
    P1, N=57, Recruiting, Kangabio AUSTRALIA LTD PTY
    New P1 trial
    |
    Enweida (envafolimab)
    2d
    Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma. (PubMed, medRxiv)
    Prior molecular studies have focused mainly on the DNAJB1-PRKACA fusion gene, which is pathognomonic for FLC, but no reliable circulating biomarker has been established for FLC diagnosis or disease monitoring...Routine measurement of serum PCT could facilitate earlier recognition of FLC and also provide a non-invasive tool to track treatment response. Future research should validate these findings prospectively, explore the biological mechanisms underlying CALCA overexpression in FLC, and assess whether PCT-guided monitoring can predict prognosis, improve patient outcomes or clinical trial design in this rare malignancy.
    Journal
    |
    AFP (Alpha-fetoprotein) • DNAJB1 (DnaJ Heat Shock Protein Family (Hsp40) Member B1) • PRKACA (Protein Kinase CAMP-Activated Catalytic Subunit Alpha) • CA 19-9 (Cancer antigen 19-9)
    |
    DNAJB1-PRKACA peptide vaccine
    2d
    Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers (clinicaltrials.gov)
    P3, N=840, Completed, Sanofi Pasteur, a Sanofi Company | Active, not recruiting --> Completed
    Trial completion
    2d
    Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection (clinicaltrials.gov)
    P1, N=27, Active, not recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting --> Active, not recruiting | N=40 --> 27 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    iNeo-Vac-P01
    3d
    Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age (clinicaltrials.gov)
    P3, N=2457, Completed, ModernaTX, Inc. | Active, not recruiting --> Completed
    Trial completion